Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.33 |
| ▸ | FDPS | P14324 | 3/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17793809 | 0.93 | — | — | |
| SCHEMBL19124347 | 0.79 | EBP (0.34) | DNM1FDPSGBA1LMNA | |
| SCHEMBL24319599 | 0.75 | PTGER4 (0.32) | FDPS | |
| SCHEMBL24611112 | 0.74 | FDPS (0.38) | DNM1FDPSLMNA | |
| SCHEMBL23733463 | 0.73 | FDPS (0.34) | FDPSLMNA | |
| SCHEMBL23844840 | 0.71 | CHRNB2 (0.38) | DNM1FDPSGBA1LMNA | |
| SCHEMBL23844581 | 0.71 | CHRNB2 (0.38) | DNM1FDPSGBA1LMNA | |
| SCHEMBL20090784 | 0.71 | DPP4 (0.33) | FDPS | |
| SCHEMBL24611066 | 0.70 | LMNA (0.35) | FDPSGBA1LMNA | |
| SCHEMBL25062773 | 0.70 | ALDH1A1 (0.34) | FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220202788-A1 | FORMULATIONS OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE | LOXO ONCOLOGY, INC. | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202788-A1 | FORMULATIONS OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE | RET, ALK, BRAF | DNM1 4538/4885FDPS 3086/4885GBA1 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.